• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

OXiGENE appoints Kollins to business development post

Article

Waltham, MA-OXiGENE Inc., a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced that John A. Kollins has joined the company as senior vice president and chief business officer. In the latter role, Kollins will be responsible for all business development activities as well as commercial strategy for the company.

Waltham, MA-OXiGENE Inc., a clinical-stage biotechnology company developing novel therapeutics to treat cancer and eye diseases, announced that John A. Kollins has joined the company as senior vice president and chief business officer. In the latter role, Kollins will be responsible for all business development activities as well as commercial strategy for the company.

Kollins has nearly 20 years of pharmaceutical and biotechnology industry experience, specifically in strategic marketing, new product development, and business development. He also has significant experience working with investors and most recently served as an independent consultant to a health-care-focused investment fund as well as several public and private biopharmaceutical companies.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.